Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer

X
Trial Profile

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etrumadenant (Primary) ; Quemliclustat (Primary) ; Zimberelimab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin; Regorafenib
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARC-9
  • Sponsors Arcus Biosciences
  • Most Recent Events

    • 24 Apr 2024 According to a Arcus Biosciences media release, data from the study will be presented as oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 June 4, 2024.
    • 05 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jul 2024.
    • 05 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jul 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top